Tretinoin (ATRA)
Vesanoid · Retinoid (differentiating agent)
Differentiation syndrome → capillary leak and AKI.
Elzonris · Tagrax
IL-3 immunotoxin · approved 2018 · 7 citations · FAERS AKI reporting ROR 4.37 (95% CI 2.90–6.58, 24 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A CD123-directed diphtheria-toxin fusion whose capillary leak can collapse the circulation and the kidneys.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Capillary leak syndrome (CLS) is a boxed-warning toxicity occurring in ~19-21% of treated patients in the registrational trial (mostly grade 2; grade >=3 in ~4% — 2% grade 3 plus 2% grade 4 — with two deaths); the resulting hypotension, hypoalbuminemia, and fluid shifts can precipitate prerenal AKI and, with prolonged hypoperfusion, ischemic ATN. Renal-specific AKI incidence is not separately quantified.Source: Pemmaraju et al., J Clin Oncol 2022
Usually during the first cycle, often within days of the first doses.
Distilled from: “Typically during the first treatment cycle, often within days of the first doses; recurrence in later cycles is uncommon with proactive monitoring.”
Recurrence in later cycles is uncommon with proactive monitoring.
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Capillary leak syndrome in 19% of patients in the pivotal BPDCN trial (fatal in one patient per dose subgroup); CLS drives intravascular volume depletion / prerenal physiology
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Recombinant fusion of interleukin-3 (IL-3) and truncated diphtheria toxin that binds the IL-3 receptor alpha chain (CD123) overexpressed on malignant cells, internalizes, and the diphtheria-toxin payload ADP-ribosylates elongation factor 2 to halt protein synthesis and trigger apoptosis. First approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Vasculature / Endothelium
Glomerular & peritubular capillaries
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Dec 2024) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: CAPILLARY LEAK SYNDROME Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete boxed warning. Capillary Leak Syndrome (CLS), which may be life-threatening or fatal if not properly managed, can occur in patients receiving ELZONRIS. ( 5.1 )
Kidney rows of the label's dosage tables
From the Elzonris label (Dec 2024) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.
| Serum creatinine | Serum creatinine > 1.8 mg/dL (159 micromol/L) or creatinine clearance < 60 mL/minute | Withhold ELZONRIS until serum creatinine resolves to ≤ 1.8 mg/dL (159 micromol/L) or creatinine clearance ≥ 60 mL/minute. |
Everything below is FAERS — adverse events someone chose to report, about 538 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
161 of 538 reports
Reported with hospitalization
135 of 538 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Tagraxofusp sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Vesanoid · Retinoid (differentiating agent)
Differentiation syndrome → capillary leak and AKI.
Lumakras · KRAS G12C inhibitor
Newer agent; renal data emerging.
Talvey · Bispecific (GPRC5D×CD3)
CRS-related AKI — emerging.
Tecvayli · Bispecific (BCMA×CD3)
CRS-associated AKI in myeloma — emerging signal.
Beromun · Recombinant TNF-α (cytokine)
Isolated-limb-perfusion agent; systemic leakage → SIRS/hypotension → prerenal AKI.
Trisenox · Differentiating agent
Differentiation syndrome; QT prolongation.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.